Companies › Vanda Pharmaceuticals
9 active drug programs in 17 registered trials: 11 Phase 3, 3 Phase 2, 2 Phase 1, 1 Phase 4; Psychiatry, Neurology, Metabolic and endocrine, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| iloperidone Dopamine D2 receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist | DRD2, HTR2A | Phase 4 | Schizophrenia; Hypertension | Nov 2026 |
| Tradipitant Neurokinin 1 receptor antagonist | TACR1 | Phase 3 | Idiopathic Gastroparesis; Nausea and Vomiting; Motion Sickness | Dec 2026 |
| VQW-765 | – | Phase 3 | Social Anxiety Disorder (SAD) | Dec 2026 |
| Tasimelteon Melatonin receptor agonist | MTNR1A, MTNR1B | Phase 3 | Sleep Wake Disorders; Insomnia Disorder | Nov 2027 |
| Milsaperidone 5-HT1A receptor partial agonist | HTR1A | Phase 3 | Major Depressive Disorder (MDD) | Mar 2028 |
| Ponesimod Sphingosine 1-phosphate receptor Edg-1 agonist | S1PR1 | Phase 3 | Moderate-to-severe Chronic Plaque Psoriasis; Ulcerative Colitis (UC) | Aug 2028 |
| Trichostatin A (VTR-297) | – | Phase 2 | Onychomycosis of Toenail; Relapsed or Refractory Hematologic Malignancies | Dec 2027 |
| VSJ-110 | – | Phase 2 | Dry Eye | – |
| VCA-894A antisense oligonucleotide targeting IGHMBP2 | IGHMBP2 | Phase 1 | Charcot Marie Tooth Disease (CMT) | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06701396 | Tasimelteon | Phase 3 | Sleep Wake Disorders | Neurology | Jun 2025 |
| NCT06836557 | Tradipitant | Phase 3 | Idiopathic Gastroparesis | Metabolic and endocrine | Mar 2026 |
| NCT04652882 | Tasimelteon | Phase 3 | Sleep Wake Disorders | Neurology | Sep 2026 |
| NCT07065773 | Trichostatin A (VTR-297) | Phase 2 | Onychomycosis of Toenail | Infectious disease | Sep 2026 |
| NCT07179055 | VSJ-110 | Phase 2 | Dry Eye | Ophthalmology | Sep 2026 |
| NCT07090161 | iloperidone | Phase 2 | Hypertension | Cardiovascular | Nov 2026 |
| NCT07446439 | Tradipitant | Phase 3 | Nausea and Vomiting | Metabolic and endocrine | Dec 2026 |
| NCT07221578 | VQW-765 | Phase 3 | Social Anxiety Disorder (SAD) | Psychiatry | Dec 2026 |
| NCT07223632 | VCA-894A | Phase 1 | Charcot Marie Tooth Disease (CMT) | Neurology | Mar 2027 |
| NCT06138613 | Tradipitant | Phase 3 | Motion Sickness | Other | Sep 2027 |
| NCT06953869 | Tasimelteon | Phase 3 | Insomnia Disorder | Psychiatry | Nov 2027 |
| NCT06961968 | iloperidone | Phase 3 | Schizophrenia | Psychiatry | Nov 2027 |
| NCT03838926 | Trichostatin A (VTR-297) | Phase 1 | Relapsed or Refractory Hematologic Malignancies | Oncology | Dec 2027 |
| NCT06830044 | Milsaperidone | Phase 3 | Major Depressive Disorder (MDD) | Psychiatry | Mar 2028 |
| NCT07362017 | Ponesimod | Phase 3 | Moderate-to-severe Chronic Plaque Psoriasis | Immunology | Aug 2028 |
| NCT05648591 | iloperidone | Phase 4 | Schizophrenia | Psychiatry | Dec 2028 |
| NCT07686081 | Ponesimod | Phase 3 | Ulcerative Colitis (UC) | Immunology | Apr 2029 |
Cash of $62m on 2026-09-30; operating cash outflow about $147m a year; runway about 5 months at that burn, to Mar 2027; 3 of 6 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Intra-Cellular Therapies Neurocrine Biosciences VistaGen Therapeutics Alkermes ARS Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.